Skip to main
APGE

APGE Stock Forecast & Price Target

APGE Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Apogee Therapeutics Inc's stock outlook is enhanced by its upcoming clinical data catalysts for APG777, particularly the anticipation of best-in-class efficacy and safety in atopic dermatitis, with data expected in 1Q26. The biotechnology firm is positioned within a lucrative market, as demonstrated by Dupixent's remarkable growth, which saw over $14 billion in global sales in 2024 and is projected to exceed $20 billion, highlighting the substantial revenue potential for Apogee's innovative therapies targeting high unmet medical needs. Additionally, with ongoing growth in the biologic market for inflammatory and immunology indications, along with APG777's competitive advantages in dosing and efficacy, Apogee Therapeutics stands to capitalize significantly from expanding market opportunities.

Bears say

Apogee Therapeutics Inc faces significant risks that could hinder its financial performance and stock viability, including the possibility of developmental setbacks in its pipeline programs, unexpected safety signals, and challenges in securing regulatory approval for its drug candidates. The company may encounter efficacy issues with its treatments, leading to potential commercialization difficulties and the inability to secure revenue-generation capabilities. Furthermore, its reliance on successfully navigating trials and maintaining funding amidst a revenue-less environment adds to the uncertainties surrounding its financial outlook and overall market position.

APGE has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apogee Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apogee Therapeutics Inc (APGE) Forecast

Analysts have given APGE a Strong Buy based on their latest research and market trends.

According to 9 analysts, APGE has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $101.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $101.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apogee Therapeutics Inc (APGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.